WO2012052478A3 - Topical gel composition - Google Patents

Topical gel composition Download PDF

Info

Publication number
WO2012052478A3
WO2012052478A3 PCT/EP2011/068261 EP2011068261W WO2012052478A3 WO 2012052478 A3 WO2012052478 A3 WO 2012052478A3 EP 2011068261 W EP2011068261 W EP 2011068261W WO 2012052478 A3 WO2012052478 A3 WO 2012052478A3
Authority
WO
WIPO (PCT)
Prior art keywords
topical gel
gel composition
paraben
gel compositions
treatment
Prior art date
Application number
PCT/EP2011/068261
Other languages
French (fr)
Other versions
WO2012052478A2 (en
Inventor
Jean-Christophe Buge
Karine Nadau Fourcade
Cyril Meunier
Original Assignee
Galderma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1058611A external-priority patent/FR2966365B1/en
Priority to BR112013009577A priority Critical patent/BR112013009577A2/en
Priority to CA2814975A priority patent/CA2814975A1/en
Priority to JP2013534308A priority patent/JP2013540142A/en
Priority to CN2011800509124A priority patent/CN103313700A/en
Priority to SG2013026679A priority patent/SG189338A1/en
Application filed by Galderma S.A. filed Critical Galderma S.A.
Priority to EP11771146.5A priority patent/EP2605753A2/en
Priority to RU2013123043/15A priority patent/RU2013123043A/en
Priority to KR1020137012906A priority patent/KR20130101552A/en
Priority to AU2011317642A priority patent/AU2011317642A1/en
Priority to MX2013004472A priority patent/MX2013004472A/en
Publication of WO2012052478A2 publication Critical patent/WO2012052478A2/en
Publication of WO2012052478A3 publication Critical patent/WO2012052478A3/en
Priority to ZA2013/02812A priority patent/ZA201302812B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Abstract

Improved topical gel compositions, such as those containing brimonidine for the treatment of skin disorders are described. The gel compositions contain carbomer and paraben, and are substantially free of paraben crystalline particles after an extended period of storage.
PCT/EP2011/068261 2010-10-21 2011-10-19 Topical gel composition WO2012052478A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
MX2013004472A MX2013004472A (en) 2010-10-21 2011-10-19 Topical gel composition.
RU2013123043/15A RU2013123043A (en) 2010-10-21 2011-10-19 GEL COMPOSITION FOR LOCAL USE
JP2013534308A JP2013540142A (en) 2010-10-21 2011-10-19 Topical gel composition
CN2011800509124A CN103313700A (en) 2010-10-21 2011-10-19 Topical gel composition
SG2013026679A SG189338A1 (en) 2010-10-21 2011-10-19 Topical gel composition
BR112013009577A BR112013009577A2 (en) 2010-10-21 2011-10-19 topical gel composition and method
EP11771146.5A EP2605753A2 (en) 2010-10-21 2011-10-19 Topical gel composition
CA2814975A CA2814975A1 (en) 2010-10-21 2011-10-19 Topical gel composition
KR1020137012906A KR20130101552A (en) 2010-10-21 2011-10-19 Topical gel composition
AU2011317642A AU2011317642A1 (en) 2010-10-21 2011-10-19 Topical gel composition
ZA2013/02812A ZA201302812B (en) 2010-10-21 2013-04-18 Topical gel composition

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40538210P 2010-10-21 2010-10-21
US61/405,382 2010-10-21
FR1058611A FR2966365B1 (en) 2010-10-21 2010-10-21 TOPICAL GEL COMPOSITION
FR1058611 2010-10-21

Publications (2)

Publication Number Publication Date
WO2012052478A2 WO2012052478A2 (en) 2012-04-26
WO2012052478A3 true WO2012052478A3 (en) 2012-06-14

Family

ID=45065557

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/068261 WO2012052478A2 (en) 2010-10-21 2011-10-19 Topical gel composition

Country Status (13)

Country Link
EP (1) EP2605753A2 (en)
JP (1) JP2013540142A (en)
KR (1) KR20130101552A (en)
CN (1) CN103313700A (en)
AU (1) AU2011317642A1 (en)
BR (1) BR112013009577A2 (en)
CA (1) CA2814975A1 (en)
IL (1) IL225775A0 (en)
MX (1) MX2013004472A (en)
RU (1) RU2013123043A (en)
SG (1) SG189338A1 (en)
WO (1) WO2012052478A2 (en)
ZA (1) ZA201302812B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130079379A1 (en) * 2011-07-14 2013-03-28 Allergan, Inc. Gel compositions of oxymetazoline and methods of use
CN104666239A (en) * 2013-11-27 2015-06-03 杭州赛利药物研究所有限公司 Brimonidine tartrate gel and preparation method thereof
CN103919717A (en) * 2014-04-15 2014-07-16 天津中医药大学 Brimonidine d-tartrate ophthalmic gel preparation as well as preparation method and application thereof
US10744135B2 (en) * 2016-06-28 2020-08-18 Doris Maria HEXSEL Use of an active substance in the treatment of melasma
CA3137267A1 (en) 2019-05-01 2020-11-05 Clexio Biosciences Ltd. Methods of treating pruritus
CN110882211A (en) * 2019-12-31 2020-03-17 深圳市瀚德标检生物工程有限公司 Hydroxyphenyl ester gel and preparation method thereof
CN116159018A (en) * 2023-03-01 2023-05-26 中国药科大学 Novel external brimonidine gel

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242588A1 (en) * 2003-05-27 2004-12-02 Jack Dejovin Compounds, formulations, and methods for treating or preventing rosacea
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
WO2009082452A1 (en) * 2007-12-21 2009-07-02 Dejovin Jack A Pre-surgical treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006A (en) * 1852-06-08 Improvement in seed-planters
US20050020600A1 (en) 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
CA2824612C (en) * 2004-05-25 2016-08-16 Galderma Pharma S.A. Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
WO2009065116A1 (en) 2007-11-16 2009-05-22 Aspect Pharmaceuticals Llc Compositions and methods for treating purpura
JP5052558B2 (en) * 2009-04-03 2012-10-17 ロート製薬株式会社 Gel ointment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242588A1 (en) * 2003-05-27 2004-12-02 Jack Dejovin Compounds, formulations, and methods for treating or preventing rosacea
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
WO2009082452A1 (en) * 2007-12-21 2009-07-02 Dejovin Jack A Pre-surgical treatment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GERMAN L. PERLOVICH, SERGEY V. RODIONOV, ANNETTE BAUER-BRANDL: "Thermodynamics of solubility, sublimation and solvation processes of parabens", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 24, 11 November 2004 (2004-11-11), pages 25 - 33, XP002631269 *
GIORDANO F, BETTINI R, DONINI C, GAZZANIGA A, CAIRA MR, ZHANG GG, GRANT DJ.: "Physical properties of parabens and their mixtures: solubility in water, thermal behavior, and crystal structures.", J PHARM SCI., vol. 88, no. 11, November 1999 (1999-11-01), pages 1210 - 1216, XP002631268 *

Also Published As

Publication number Publication date
CN103313700A (en) 2013-09-18
BR112013009577A2 (en) 2016-07-12
SG189338A1 (en) 2013-05-31
KR20130101552A (en) 2013-09-13
MX2013004472A (en) 2013-10-25
JP2013540142A (en) 2013-10-31
CA2814975A1 (en) 2012-04-26
IL225775A0 (en) 2013-09-30
EP2605753A2 (en) 2013-06-26
WO2012052478A2 (en) 2012-04-26
ZA201302812B (en) 2014-06-25
AU2011317642A1 (en) 2013-05-02
RU2013123043A (en) 2014-12-10

Similar Documents

Publication Publication Date Title
WO2012052479A3 (en) Brimonidine gel compositions and methods of use
WO2012065022A3 (en) Spiro-oxindole mdm2 antagonists
WO2011082266A3 (en) Substituted heterocyclic compounds
WO2011060049A3 (en) Spiro-oxindole mdm2 antagonists
WO2012052478A3 (en) Topical gel composition
WO2012177844A3 (en) Substituted imidazopyridinyl-aminopyridine compounds
WO2011082273A3 (en) Substituted pyrrolo-aminopyrimidine compounds
WO2011082270A3 (en) Substituted imidazopyridinyl-aminopyridine compounds
WO2011082267A8 (en) Substituted triazolo-pyrazine compounds
CA2871471C (en) Dna-pk inhibitors
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
CA2894891A1 (en) Boronic acid derivatives and therapeutic uses thereof
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
WO2012016186A8 (en) Macrocyclic kinase inhibitors and uses thereof
WO2012055567A3 (en) Use of malononitrilamides in neuropathic pain
WO2011107462A3 (en) Sun protection compositions
WO2012048099A3 (en) Nanoparticle-loaded cells
WO2012030984A3 (en) Skin compositions and methods of use thereof
WO2011123678A3 (en) Substituted benzo-pyrido-triazolo-diazepine compounds
UA109868C2 (en) N -alkyltriazole compounds asr
WO2012090043A8 (en) Novel solid state forms of azilsartan medoxomil and preparation thereof
WO2012021715A3 (en) Stable formulations of linaclotide
WO2011085162A3 (en) Topical transdermal dexmedetomidine compositions and methods of use thereof
MX2014010724A (en) Phenicol antibacterials.
WO2013061004A8 (en) Novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11771146

Country of ref document: EP

Kind code of ref document: A2

REEP Request for entry into the european phase

Ref document number: 2011771146

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011771146

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12013500679

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2814975

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013534308

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/004472

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2011317642

Country of ref document: AU

Date of ref document: 20111019

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20137012906

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2013123043

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013009577

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013009577

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130419